Bavarian on lacking coronavirus vaccine funding: Sponsors prioritize speed over quality
Bavarian Nordic and Adaptvac have yet to acquire the necessary financing for their vaccine against Covid-19. Bavarian maintains that it has an excellent candidate at hand.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Technically, a postponed phase III trial with a vaccine candidate for the respiratory virus RSV should have cleared space for Bavarian Nordic to do clinical trials with the vaccine for Covid-19 for which Bavarian Nordic has acquired the rights from the smaller Danish company Adaptvac.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Danish Covid-19 vaccine might be ready before 2021
For subscribers
Bavarian dreams of big US sales after good vaccine data
For subscribers
